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Introduction
Obsessive–compulsive disorder (OCD) is the fourth most 
common mental disorder, with a lifetime prevalence of 1% to 
3%. Patients with OCD are characterized by recurrent intru-
sive thoughts (obsessions), unwanted repetitive behaviours 
(compulsions) or most commonly by both types of clinical 
symptoms.1 Obsessive–compulsive disorder was ranked 
among the top 10 most handicapping conditions in terms of 
decreased quality of life. The disorder has also been identi-
fied as a leading global cause of nonfatal illness by the World 
Health Organization.2,3 People with OCD often experience 
impairments in social and occupational functioning.3 First-
line treatments for OCD involve cognitive behavioural ther-
apy with exposure and response prevention, and pharmaco-
therapy with serotonin reuptake inhibitors.4 Although most 
patients experience adequate relief from OCD symptoms 
with cognitive behavioural therapy and medication, about 
30% to 40% of affected patients fail to respond to these treat-
ment modalities.5,6
Neurosurgical interventions have long been used as a last 
resort for rare cases of severe and treatment-resistant OCD in 
many medical centres.1,7 Since the first published report of 
prefrontal leucotomy for “obsessional neurosis” in 1947,8 ab-
lative surgery has been explored as a valuable neurosurgical 
treatment option for OCD. Recent meta-analyses have sug-
gested that neuroablation is more effective for OCD than its 
psychiatric neurosurgery counterpart, deep brain stimulation 
(DBS).8–10 The clinical use of ablative interventions is based on 
the assumption that these procedures can resolve dysfunc-
tion in cortico–striato–thalamo–cortical circuitry, which is be-
lieved to underlie the pathophysiology of OCD and response 
to treatment, as evidenced by electrophysiological and func-
tional neuroimaging studies.11
Surgical studies of patients with severe and treatment-
resistant OCD have employed 4 main neuroablative 
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Background: Several neuroablative procedures are available for severe and treatment-resistant obsessive–compulsive disorder (OCD), 
but limited knowledge about their relative clinical advantages and disadvantages poses obstacles for treatment decision-making.  Methods: 
We searched PubMed, Embase, Scopus, Web of Knowledge and the Cochrane Library for reports up to February 2019. We reviewed the 
literature on the effectiveness (assessed using the Yale–Brown Obsessive Compulsive Scale [Y-BOCS]) and safety of various neuroabla-
tive interventions for severe and treatment-resistant OCD. Results: We included 23 studies involving 487 patients in the systematic review; 
21 studies with 459 patients were included in the meta-analysis. Overall, neuroablation achieved a response rate (proportion of patients with 
≥ 35% reduction in Y-BOCS) of 55%. Most of the adverse events (88.4%) were mild and transient. The top 3 adverse events were head-
ache (14.9%), cognitive deficits (9.1%) and behaviour problems (8.1%). Severe or permanent adverse events included personality changes 
(2.3%) and brain edema or brain cyst (1.5%). The response rates associated with capsulotomy, limbic leucotomy and cingulotomy were 
59% (95% confidence interval [CI] 54–65), 47% (95% CI 23–72) and 36% (95% CI 23–50), respectively. Interventions with different cover-
ages of the dorsal part of the internal capsule were associated with different adverse-event profiles but were unlikely to modify clinical effec-
tiveness. Limitations: The level of evidence of most included studies was relatively low. Conclusion: Ablative surgeries are safe and effec-
tive for a large proportion of patients with severe and treatment-resistant OCD. Among the available procedures, capsulotomy seemed to be 
the most effective. Further research is needed to improve clinical effectiveness and minimize risks.
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 procedures, which target different brain structures and net-
works: anterior capsulotomy (anterior limb of the internal 
capsule [ALIC]), cingulotomy (anterior cingulate cortex and 
the fibres of the cingulum), subcaudate tractotomy (fronto-
thalamic fibres) and limbic leucotomy (a combination of an-
terior cingulotomy and subcaudate tractotomy).1 The clinical 
utility of these procedures has been examined separately in 
different studies. However, there exists no original study to 
date comparing the safety and clinical effectiveness (as-
sessed using the standard Yale–Brown Obsessive Com-
pulsive Scale [Y-BOCS]12) of these different neuroablative 
procedures with each other.13 This gap in the literature makes 
it difficult for clinicians and patients to make an informed 
 decision about which neuroablative intervention to choose. 
At present, specific treatment decisions are still based largely 
on individual hospitals’ expertise and experience in perform-
ing a certain neuroablative procedure. No data are available 
to support the application of one procedure over another in 
terms of its effectiveness or safety profile.14
In this study, we aimed to gain a better understanding of 
the relative clinical advantages and disadvantages of the 
various neuroablative interventions used for severe and 
treatment-resistant OCD. We conducted a systematic review 
and meta-analysis of the reported clinical benefits and 
risks of the different neuroablative interventions for OCD. 
We also explored whether interventions that differentially 
covered areas of the internal capsule were associated with 
different clinical outcomes. The study results should provide 
a better understanding of the effectiveness and safety of the 
main neuroablative interventions currently available for 
severe and otherwise treatment-resistant OCD.
Methods
Search strategy
We performed a literature search using the following 
databases (from inception to February 2019): PubMed, 
Embase, Scopus, Web of Knowledge and the Cochrane 
Library. The MESH terms (PubMed), EMTREE terms 
(Embase) and key words (others) we used were as follows: 
“obsessive–compulsive disorder,” “stereotactic,” “ablation,” 
“psychosurgery,” “capsulotomy,” “cingulotomy” and 
“tractotomy.” We also reviewed the reference lists of retrieved 
articles and reviews to find additional relevant studies.
Selection criteria
The inclusion criteria applied to the records retrieved were as 
follows: original human studies assessing the effectiveness of 
neuroablative surgery for OCD; treatment effectiveness 
meas ured using the Y-BOCS in terms of response rate 
 (responders, partial responders and nonresponders were de-
fined as showing reductions ≥ 35%, 35% to 25%, and < 25%, 
respectively, in total Y-BOCS score at final follow-up com-
pared with baseline)15 or the absolute or relative (%) change 
in total Y-BOCS score from baseline to final follow-up; and 
written in English.
Exclusion criteria were as follows: animal studies, litera-
ture reviews, comments or correspondences, conference ab-
stracts, patents, case reports or case series involving fewer 
than 3 patients; a lack of either pre- or postoperative Y-BOCS 
data; reports on the same patients at multiple follow-up 
 assessments (in these cases, only the report with the final or 
most recent follow-up was included); results involving 
combinations of neuroablation and DBS; and a lack of infor-
mation about the exact neuroablative procedure used (e.g., 
mentioning only “psychosurgery” or “psychiatric neurosur-
gery” as the intervention).
Data extraction
Two investigators (Y.L. and T.W.) independently extracted 
the following information from the included studies: study 
characteristics (OCD diagnostic criteria, inclusion and exclu-
sion criteria and clinical outcome measures); sample size and 
demographic characteristics (sex, age at surgery, age at onset 
of OCD, duration of OCD and duration of follow-up); sur-
gical variables (target, lesion technique and size of lesion); re-
sponse rate, which was used as the primary effectiveness 
measure in this review; percent or absolute change in total 
Y-BOCS score, as well as outcomes related to depression and 
anxiety, which served as secondary outcome measures; the 
number and nature of adverse effects, which were first classi-
fied as either “mild and transient” or “severe or permanent” 
and then categorized according to 4 main classes (surgery-
related, neurologic, neurobehavioural and other [e.g., weight 
change]). We imputed a missing response-rate value at last 
follow-up in the study of Csigo and colleagues16 using the 
mean value of the studies included in our meta-analysis.
To explore whether interventions with different coverages 
of internal capsule areas were associated with different clin-
ical outcomes, we visually checked the postsurgical MRI 
 images presented in the publications to match the targets to 
the lesion and categories proposed by Miguel and colleagues 
in 2018.17 Based on the contour of the 20% isodose line, the 
authors defined 4 categories to describe different coverages 
of the internal capsule. In our meta-analysis, we were able to 
put patients into 3 subgroups based on the target description 
or postsurgical MRI images: T group, with lesion areas com-
parable to 3 isocentres covering the majority of the ALIC; 
D group, with lesion areas comparable to double shots cover-
ing the ventral third of the anterior capsule/ventral striatum; 
and S group, with lesion areas comparable to a single isocen-
tre covering the ventral capsule. 
Data synthesis and meta-analysis
We used weighted-proportion analysis to adjust for study 
size using the DerSimonian–Laird model, taking the esti-
mate of heterogeneity from the inverse-variance fixed-effect 
model. We constructed a forest plot to show study-level 
 estimates, pooled estimates across studies (and 95% confi-
dence intervals [CIs]) and the relative weighted contribu-
tion of each study. We assessed heterogeneity using Q sta-
tistics and the I2 index; values of p < 0.1 for the former and 
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> 35% for the latter were deemed to be indicative of be-
tween-study heterogeneity. We used subgroup analyses to 
assess the effect of surgical covariates on the effectiveness of 
treatment. Because the majority of the included studies were 
observational and noncomparative, direct statistical com-
parisons between groups were inappropriate; therefore, we 
combined individual study results only within their respec-
tive groups. We calculated effectiveness values for the fol-
lowing: subgroups with different neuroablation procedures, 
subgroups with different coverage of internal capsule areas 
(T, D and S) and subgroups with different numbers of repeat 
procedures (yes: >  80% of patients received repeat pro-
cedures; mixed: 20% to 80% of patients received repeat 
procedures; no: < 20% of patients received repeat proced-
ures). We performed multivariate random-effects meta- 
regression using aggregate-level data to analyze correla-
tions between outcomes and covariates (mean last 
follow-up period, mean age at surgery, mean age at disease 
onset, mean duration of illness and mean preoperative total 
Y-BOCS score). We conducted Begg’s test and funnel plot 
analysis to detect potential publication bias.
Results
Literature search
Figure 1 presents study selection and the reasons for study 
exclusion. Our initial search retrieved 3003 studies. After we 
removed duplicates and screened titles and abstracts, we 
kept 92 studies for full-text review. Finally, we included 
23 studies with a total of 487 patients16,18–39 in the review and 
21 studies with a total of 459 patients16,18–20,22,24–39 in the meta-
analysis.
Main characteristics of included studies
We separated the data from 5 studies into 12 data sets 
based on the type of surgical technique used in their patient 
sample,21,31,32,34,36 resulting in 30 data sets from 23 included 
studies, and incorporating 487 patients and 562 procedures 
(combinations of different surgeries at a single operation 
time were counted as a single procedure). The main charac-
teristics of the included studies are described in Table 1 and 
Appendix 1, Tables S1 and S2 (available at jpn.ca/190079-a1). 
Among the procedures, capsulotomy was performed most 
commonly (343 patients [70.4%] involving 16 studies), fol-
lowed by cingulotomy (62 patients [12.7%] involving 3 studies; 
Table 2). Although subcaudate tractotomy was reported in 
several studies, these studies either used symptom severity 
measures other than Y-BOCS or documented the results 
mixed with the effects of other surgeries,40–44 so no subcaudate 
tractotomy study was included in this review. Radiofre-
quency, focused ultrasonography, mechanical and other abla-
tive approaches were used for capsulotomy, but radiofre-
quency was the only approach used for ablation in other 
brain areas. For capsulotomy, radiosurgery was performed 
on 139 patients (40.5%) in 8 studies, and radiofrequency abla-
tion was performed on 174 patients (50.7%) in 7 studies.
In 1 study, a considerable number of the procedures used 
for limbic leucotomy were conducted under the guidance of 
ventriculography.23 In another, stereotactic lesions were 
made under the guidance of high-pressure pneumoventricu-
lography, but the resulting lesions comprised a vast coverage 
of brain structures, from the ventral striatum to dorsolateral 
frontal cortex.21 We excluded these 2 studies from further 
quantitative analysis, resulting in a total of 21 studies incor-
porating 459 patients. Across the 21 studies included in the 
meta-analysis, the mean duration of follow-up was 
45.4 months (range 7.6–142.0).
Treatment effectiveness
Overall and surgery-specific effectiveness
The pooled response rate at last follow-up (mean duration 
45.4 [range 7.6–142.0] months) was 55% (95% CI 50–61) for 
the whole population treated with neuroablation. Specif-
ically, the observed response rates were 59% (95% CI 54–65), 
36% (95% CI 23–50) and 47% (95% CI 23–72) following capsu-
lotomy, cingulotomy and limbic leucotomy, respectively. We 
found substantial heterogeneity (p = 0.010) between groups 
for the different surgeries, but the extent of the heterogeneity 
within each surgery group was small (I2 < 35%, p > 0.1; 
Fig. 2). Sheth and colleagues34 examined 30 patients who 
under went a repeated cingulotomy and/or an additional 
subcaudate tractotomy (resulting in a complete limbic leucot-
omy) after the failure of an initial cingulotomy. The response 
rate in this group was 53% (95% CI 34–72) at follow-up 
(mean 65.2 ± 54.6 months). Zhang and colleagues39 reported 
that a combination of cingulotomy and capsulotomy 
achieved a response rate of 71% (95% CI 29–96) at 12-month 
follow-up. Based on the studies included in our meta- 
analysis (9 data sets, 6 studies, 124 patients, all capsulot-
omy),18,20,24,27,28,31,32 we calculated a response rate of 47% (95% 
CI 37–56) at 12-month follow-up. No significant publication 
bias was present in the included studies, according to funnel 
plot analysis and Begg’s test (p = 0.28; Appendix 1, Fig. S3).
The pooled total Y-BOCS score decreased from 33.1 (95% CI 
33.0–33.3) at baseline to 19.3 (95% CI 18.9–19.7) at last 
 follow-up (mean duration 45.4 [range 7.6–142.0] months; 
Fig. 3). At 12-month follow-up, the pooled Y-BOCS score (re-
ported in 14 studies involving 337 patients) was 18.5 (95% CI 
17.8–19.2). The Y-BOCS scores at 12-month follow-up for 
 patients who underwent capsulotomy (10 studies, 249 pa-
tients) or cingulotomy (2 studies, 51 patients) were 17.5 (95% 
CI 16.8–18.3) and 21.7 (95% CI 19.3–24.0), respectively. The 
 reductions in Y-BOCS scores at 12 months (52 patients) and 
last follow-up (mean duration 40.6 months, 180 patients) were 
12.6 (95% CI 11.5–13.7) and 13.6 (95% CI 12.5–14.7;  Appendix 
1, Fig. S4). The pooled percent reductions in the  total Y-BOCS 
score at 12 months (109 patients) and last  follow-up (mean 
duration 48.0 months, 198 patients) were 32.20% (95% CI 
28.33–36.07) and 43.55% (95% CI 41.87–45.22; Appendix 1, Fig. 
S5). Specifically, the pooled reductions in Y-BOCS scores at 
last follow-up were 46.13% (95% CI 40.53–51.73) for the capsu-
lotomy group (104 patients; I2 = 0.0%; p = 0.54), 32.20% (95% 
CI 18.98–45.42) for the limbic leucotomy group (17 patients; 
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I2 = 0.0%; p = 0.18), and 24.26% (95% CI 16.08–32.44) for the 
cingulotomy group (43 patients; I2 = 45.6%; p = 0.18).
Target-specific effectiveness in capsulotomy
We also categorized patients with lesions in the internal cap-
sule into 3 groups (T, D and S) according to the site and na-
ture of their lesions based on the postsurgical MRI, as out-
lined earlier.17 We excluded 1 study from this analysis 
because the original data for specific lesions in the internal 
capsule were not reported.20 Results for the unilateral lesions 
reported by Ruck and colleagues32 were also excluded. Most 
included studies involved patients belonging to T group 
Fig. 1: Flow diagram for study selection.
 
Records identified through database 
searching (n = 3003) 
• PubMed (n = 361) 
• Embase (n = 655) 
• ISI Web of Knowledge (n = 640) 
• Scopus (n = 1318) 
• Cochrane Library (n = 29) 
Records screened 
(n = 2074) 
 
Studies included in the 
systematic review 
(n = 23) 
Studies included in the 
quantitative synthesis  
(meta-analysis) 
(n = 21) 
Records after duplicates removed 
(n = 2074) 
Additional records identified 
through other sources (n = 0) 
Records excluded (n = 1982)  
• Animal experiments (n = 301) 
• Case reports (n = 142) 
• Conference abstracts, correspondence, 
commentary (n = 153) 
• Reviews (n = 396) 
• Other diseases (n = 627) 
• Other interventions (n = 136) 
• Non-interventional studies (n = 223) 














Full-text articles assessed for eligibility  
(n = 92) 
 
Full-text articles excluded (n = 69) 
• More recent follow-up available (n = 19) 
• Did not address relevant outcome (n = 32)  
• Not in English (n = 8) 
• Original data not available (n = 6) 
• No surgical details (n = 2) 
• Lack of baseline records (n = 1) 
• Combined with deep brain  











Further excluded for quantitative analysis  
(n = 2) 
• Used ventriculography for surgical 
guidance (n = 1) 
• Used stereotaxy aid by 
pneumoventriculography (n = 1) 
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(8 studies, 9 data sets, 186 patients) and D group (6 studies, 
7 data sets, 96 patients). We identified only 5 patients who be-
longed to S group. Response rates were 58% (95% CI 50–65), 
67% (95% CI 56–77), and 80% (95% CI 28–99) for groups T, D 
and S, respectively (Fig. 4). We noted no significant hetero-
geneity between groups for response rate (p = 0.33), absolute 
reduction in total Y-BOCS score (p = 0.72) or percent reduction 
in total Y-BOCS score (p = 0.92; Appendix 1, Figs. S6 and S7). 
Rasmussen and colleagues31 examined patients with bilateral 
single-shot lesions, located centrally in the capsule (defined as 
an “original gamma knife capsulotomy target” by Miguel and 
colleagues17). At an average follow-up of 9.0 ± 0.4 months after 
the initial single-shot procedure, only 1 patient (of the 15 ex-
amined) met the criteria for a full or partial responder.31 These 
patients subsequently received a repeat  single-shot lesion 
 located ventrally to the first-stage shot, which eventually 
turned the lesion into a D group type of lesion.
Additionally, the pooled response rates in studies with 
more than 80% of patients who received repeat procedures 
(yes group), studies with 20% to 80% of patients with repeat 
procedures (mixed group) and studies with less than 20% of 
patients receiving repeat procedures (no group) were 50% 
(95% CI 36–64), 55% (95% CI 31–77) and 56% (95% CI 49–
63), respectively. We found no significant heterogeneity be-
tween groups with different proportions of repeat proced-
ures (p = 0.75; Appendix 1, Fig. S8).
Effectiveness and demographic variables
We observed no significant correlations between demo-
graphic variables (age of OCD onset, duration of OCD, age 
at surgery, preoperative Y-BOCS score, duration of follow-
up) and outcome measures (response rate and absolute and 
percent reduction in total Y-BOCS score) at final follow-up 
(Appendix 1, Table S9).
Depression and anxiety
Among the 21 studies included in the meta-analysis, 15 
(involving 19 data sets) contained outcome data on symptoms 
of depression (in 365 patients) and anxiety (in 286 patients) 
following ablative surgery (Appendix 1, Table S10). Depres-
sion symptoms were assessed using the Hamilton De-
pression Rating Scale, the Beck Depression Inventory or the 
Montgomery–Åsberg Depression Rating Scale.45–47 Anxiety 
symptoms were measured using the Hamilton Anxiety 
 Rating Scale, the Beck Anxiety Inventory, the Brief Scale of 
Anxiety, or the State–Trait Anxiety Inventory.48–51 After abla-
tive surgery, 14 data sets incorporating 310 patients (85%) 
reported significant improvement in depression symptoms 
from baseline. Likewise, 11 data sets incorporating 247 pa-
tients (86%) reported decreased anxiety following surgery.
Treatment safety
Overall adverse effects
Adverse effects (either presence or absence) were docu-
mented in 18 studies involving 395 patients (86% of the 
popu lation included in the meta-analysis); 3 studies provided 
no information about adverse effects. One study was ex-
cluded because the reported adverse effects in OCD patients 
were mixed with results from patients whose primary diag-
noses were not OCD; 2 other studies were excluded because 
information about adverse effects was not reported.29,36,37 Of 
the 395 patients in the adverse effects analysis, 307 were 
treated with capsulotomy, 17 with cingulotomy, 64 with cin-
gulotomy or limbic leucotomy, and 7 with cingulotomy com-
bined with capsulotomy. Only 7 data sets involved active 
surveillance for adverse effects, using the Systematic Assess-
ment for Treatment Emergent Effects event list or the Execu-
tion, Apathy, and Disinhibition scale.27,28,31,32 The incidence 
and nature of the reported adverse effects for each data set 
(or study) are summarized in Appendix 1, Table S11. Overall, 
across the different ablative procedures, most of the docu-
mented adverse effects (88.4% of all adverse effects) were 
transient and manageable. The top 3 most frequently re-
ported mild and transient adverse effects were postoperative 
headache (incidence 14.9%), cognitive deficits (9.1%) and 
 behaviour problems (8.1%). Severe or permanent adverse 
 effects were as follows: personality changes (2.3%), brain 
cysts or brain edema (1.5%), behaviour disorders (1.3%), 
weight change (1.0%), cognitive deficits (1.0%), urinary in-
continence (0.5%), suicide (0.5%), seizure (0.5%), subdural em-
pyema (0.3%), intracerebral hemorrhage (0.3%), pulmonary 
embolus (0.3%), hemiplegia (0.3%), disturbances of con-
sciousness (0.3%) and headache (0.3%). Overall, the median 
incidence of mild and transient adverse effects was 1.0% 
(range 0.3–14.9). The median incidence of severe or perma-
nent adverse effects was 0.5% (range 0.3–2.3).
Surgery-specific adverse effects
We found only 1 study that reported on the incidence of 
adverse effects specifically following cingulotomy (3 of 17 pa-
tients showed memory problems lasting less than 
2  months).22 Another study reported adverse effects 






Surgical procedure (n = 487)
Capsulotomy 343 (70.43) 19 (16)
Cingulotomy 62 (12.73) 3 (3)
Cingulotomy with subsequent lesions* 30 (6.16) 1 (1)
Cingulotomy with capsulotomy 7 (1.44) 1 (1)
Limbic leucotomy 29 (5.95) 3 (3)
Frontal leucotomy 16 (3.29) 3 (1)
Ablative technique (capsulotomy) (n = 343)
Radiofrequency 174 (50.73) 8 (7)
Radiosurgery 139 (40.52) 9 (8)
Focused ultrasound 11 (3.21) 1 (1)
Mechanical lesion 19 (5.54) 1 (1)
Repeat procedure (n = 487)†
Yes 54 (11.09) 3 (3)
Mixed 25 (5.13) 3 (1)
No 408 (83.78) 24 (21)
*Repeated cingulotomy or subcaudate tractotomy.
†Yes = > 80% received a repeat procedure; mixed = approximately 20% to 80% 
received a repeat procedure; no = < 20% received a repeat procedure. 
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 collapsed across patients with cingulotomy and patients with 
limbic leucotomy.34 In our analysis, we considered the ad-
verse effects of cingulotomy and limbic leucotomy together 
as the adverse effects of limbic system surgery (n = 81 for lim-
bic system surgery).34,36 Table 3 presents the results of this 
analysis. The median incidence of mild and transient effects 
was 1.7% (range 0.0–19.2) in the capsulotomy group and 0.0% 
(range 0.0–9.9) in the limbic system surgery group. The 
 median incidence rates of severe or permanent adverse ef-
fects were 0.3% (range 0.0–2.9) in the capsulotomy group and 
0.0% (range 0.0–2.5) in the limbic system surgery group.
Two cases of suicide were documented after cingulotomy: 
1 patient had a history of comorbid major depressive disor-
der (preoperative Beck Depression Inventory score 41) and 
the other patient had a history of comorbid bipolar disorder 
and presented with depression (Beck Depression Inventory 
score 39) at the time of surgery.34 Additionally, Montoya and 
colleagues29 reported a case of suicide after limbic leucotomy. 
In all 3 deaths, the patients exhibited suicidal ideation before 
surgery and had previously attempted suicide. In frontal leu-
cotomy, Irle and colleagues21 reported that 8 patients (50% of 
all patients) with extended lesions in the ventral striatum 
developed alcohol dependence (n = 6) or alcohol and benzo-
diazepine dependence (n = 2). These researchers also found 
that extension of the ventromedial frontal lesion to the dorso-
lateral prefrontal cortex was associated with a lower 
Fig. 2: Response rate at last follow-up after different neuroablation procedures. The diamond at the bottom is the pooled mean and its 95% 
confidence interval (CI) under a random-effects model. Last follow-up is expressed as mean ± standard deviation (SD) and range. cing = cin-
gulotomy; DS = double shot group; ES = estimated value for response rate; GK = gamma knife; LFU = last follow-up; limb = limbic leucotomy; 







Mean ± SD (range)N
Weight,
%ES (95% CI)
24.00 ± 0 (24–24)
84.00 (SD NR; 36–132)
12.00 ± 0 (12–12)
30.5 ± 29.7 (6–96)
24.00 ± 0 (24–24)
41.7 ± 13.5 (28–55)
36.00 ± 0 (36–36)
55.2 ± 23.3 (12–86)
48.00 ± 0 (48–48)
24.00 ± 0 (24–24)
36.00 ± 0 (36–36)
36.00 ± 0 (36–36)
139.5 ± 35.1 (84–180)
142.00 ± 46.6 (48–204)
42.7 ± 11.9 (48–96)
22.2 ± 10.5 (6–33)
41.00 ± 38.4 (6–116)
7.6 ± 8.6 (1–30)
67.5 (SD NR; 60–84)
24.00 ± 0 (24–24)
58.5 ± 60.5 (NR)
33.5 ± 12.5 (NR)
26.00 (SD NR; 6–59; n = 21)
37.4 ± 19.4 (NR)
65.2 ± 54.6 (NR)











Rasmussen et al. (DS)31
Rasmussen et al. (SS)31
Ruck et al. (bilateral GK)32
Ruck et al. (bilateral RF)32
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 performance IQ after surgery. However, the latter finding re-
mains to be explored further, given that the result was based 
on data from only 5 participants.21
Target-specific adverse effects in capsulotomy
As described earlier,17 we categorized patients who received 
capsulotomy into 3 groups (T, D and S). The percentages of 
patients in these groups with reported adverse effects (pres-
ence or absence) were 81% (150 patients), 100% (96 patients) 
and 100% (5 patients), respectively. However, the latter obser-
vation was based on only 1 study that included 5 patients.33 
Therefore, we examined only the adverse event profiles for 
patient groups T and D. For these groups, the median inci-
dence of reported severe or permanent adverse effects were 
1.3% (range 0.0–6.0) and 0.0% (range 0.0–3.1), respectively. 
The respective group median incidence rates of mild and 
transient adverse effects were 0.7% (range 0–17.3) and 1.0% 
(range 0–58.3; Appendix 1, Table S12).
In some studies, patients’ psychiatric-neurosurgical and 
neurologic adverse effects, such as delirium, confabulation 
Fig. 3: Overall Yale–Brown Obsessive Compulsive Scale (Y-BOCS) 
scales at baseline and last follow-up; scales are plotted as pooled 


















Fig. 4: Response rates at last follow-up in patient groups with different coverages of internal capsule areas (T, D and S). T group: lesion com-
parable to 3 isocentres covering the majority of the anterior limb of the internal capsule; D group: lesion comparable to double shots covering 
the ventral third of the anterior capsule/ventral striatum; S group: lesion comparable to a single isocentre covering the ventral capsule. Yellow 
circles indicate the areas of the lesion in the coronal plane. Last follow-up is expressed as mean ± standard deviation (SD) and range. CI = 
confidence interval; DS = double shot group; ES = estimated value for response rate; GK = gamma knife; LFU = last follow-up; MRgFUS = magnetic 
resonance–guided focused ultrasound; NR = not reported; RF = radiofrequency; SS = single shot repeat group. 
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and visual hallucinations, were attributed to radiation-
induced perilesional edema or radiation necrosis, 
which responded to corticosteroids within a few 
days.27,32 Radiation-induced severe adverse effects, in-
cluding cyst formation, were reported in 2 studies: 
1 study20 involved a patient who underwent gamma 
ventral capsulotomy after a failed cingulotomy pro-
cedure (equipment unknown), and the other study31 
included 3 patients who underwent gamma ventral 
capsulotomy with the model C gamma knife (maxi-
mum 180 Gy). One of the patients in the latter study 
developed radionecrosis with extensive edema requir-
ing surgical intervention.31
Discussion
This systematic review and meta-analysis indicated that 
neuroablation is a relatively effective and safe interven-
tion for rare cases of severe and treatment-resistant OCD. 
In the following sections, we summarize the results sup-
porting this general conclusion and discuss the clinical 
implications, along with addressing current challenges 
and suggesting directions for future research.
Treatment effectiveness
The overall response rate across different neuroablative 
procedures was 55% at a mean follow-up of 45.4 months 
(range 7.6–142). Among the 3 main neuroablative pro-
cedures reviewed, the response rate associated with cap-
sulotomy (59%) was higher than the response rates seen 
with limbic leucotomy (47%) and cingulotomy (36%). 
The response rate data were substantiated by using the 
Y-BOCS as a continuous measure of clinical response. 
The mean percent reductions in total Y-BOCS score 
were 46% in the capsulotomy group, 32% in the limbic 
leucotomy group and 24% in the cingulotomy group. 
Based on these results, we tentatively concluded that 
each ablative procedure was able to produce a clinically 
meaningful improvement in the core symptoms of 
OCD. Moreover, the response rate with capsulotomy 
may have been higher than the rates seen with cingulot-
omy and limbic leucotomy, although this result could 
not be statistically confirmed because of a lack of com-
parative studies.13 Both conclusions should be further 
qualified, however, because large interindividual pa-
tient differences typically exist in clinical response to 
 ablative surgery: some patients show significant clinical 
improvements, and other patients experience little or no 
symptomatic relief after surgery.
Additionally, improvement in the clinical symptoms 
of OCD after ablative surgery was already evident at 
12-month follow-up. Although the response rate to cap-
sulotomy at 12-month follow-up was 47%, which ap-
peared to be inferior to the observed response rate of 
59% at last follow-up, we did not observe a significant 
correlation between the duration of follow-up and 
clinical outcome measures, and this was in line with 
Table 3: Adverse effects in capsulotomy and limbic system surgery
Adverse effect Capsulotomy, % Limbic system surgery, %
Surgery-related
Severe or permanent
Brain edema or cyst 1.6 1.2
Intracerebral hemorrhage 0.3 0.0
Subdural empyema 0.0 1.2
Mild and transient
Brain edema or cyst 2.6 0.0
Asymptomatic lacunar infarct 2.0 0.0
Skin edema 1.3 0.0
Deep vein thrombosis 1.0 0.0
Fever 1.0 0.0
Intracerebral hemorrhage 1.0 0.0
Pneumonia 0.3 0.0
Sore throat 0.3 0.0
Urinary infection 0.3 0.0
Neurological
Severe or permanent
Cognitive deficits 1.3 0.0
Urinary incontinence 0.7 0.0
Hemiplegia 0.3 0.0
Seizure 0.3 1.2




Cognitive deficits 9.1 9.9
Vestibular symptoms 9.1 0.0
Urinary incontinence 6.2 1.2




Abdominal discomfort 1.0 0.0
Seizure 0.3 4.9
Urinary retention 0.0 2.5
Sialorrhea 0.3 0.0
Muscle pain 0.3 0.0
Neurobehavioural
Severe or permanent
Personality changes 2.9 0.0
Behaviour disorder* 1.6 0.0
Suicide 0.0 2.5
Mild and transient
Behaviour disorder* 10.4 0.0
Mood changes† 6.5 0.0
Personality changes 2.0 4.9
Other
Severe or permanent
Weight change 1.6 1.2
Mild and transient
Weight change 5.9 0.0
Median incidence (range)
Severe or permanent 0.3 (0.0–2.9) 0.0 (0.0–2.5)
Mild and transient 1.7 (0.0–19.2) 0.0 (0.0–9.9)
Capsulotomy group, n = 307; limbic system surgery group, n = 81. 
*Including sexual disinhibition, insomnia, increased appetite, hypersomia, somnolence, slurred 
speech and childish behaviour.
†Including depression, anxiety and mania.
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the results of 2 previous systematic reviews.14,52 Although 
it has been suggested that specific ablation techniques can 
be relevant to the response trend (e.g., gamma knife lesions 
in white matter, which develop gradually over a few weeks 
or months, delaying the clinical effect), the therapeutic ef-
fects of neuroablative interventions resulted from functional 
interruption; reorganization would occur and would largely 
stabilize in some patients within the first year after sur-
gery.24,31,32,34 Therefore, it seems unlikely that the ablative 
procedures reviewed here would take several years to ex-
hibit their therapeutic effects. Also, it is conceivable that the 
symptoms of nonresponders improved in the first year of 
treatment, but failed to maintain this initial speed of recov-
ery.18 Unfortunately, the overall database is currently lim-
ited and did not allow us to draw any firm conclusions 
about the timing of the clinical response in the first year 
 after ablative surgery.
This meta-analysis substantiated and extended the results 
of 2 previous systematic reviews on the effectiveness and 
safety of neuroablation for severe and treatment-resistant 
OCD.14,52 One of these reviews, which included 2 studies of 
anterior cingulotomy (81 patients) and 8 studies of anterior 
capsulotomy (112 patients), reached the conclusion that both 
ablative procedures were effective.14 However, this review 
was limited by the fact that it examined a relatively small 
number of studies and patients. In the other review, the focus 
was on contrasting ablative surgery to DBS; little attention 
was given to the different ablative procedures used in the 
studies.52 Moreover, the authors provided no information 
about the clinical effects of lesions in different parts of the 
 internal capsule. 
In this review, we observed that capsulotomy was the 
most commonly performed ablative surgery (about 70% of all 
patients received this procedure; n = 343). We further cat-
egorized patients with lesions in the internal capsule into 
3  groups (T, D and S) based on target descriptions and post-
surgical MRI scans.17 In this analysis, patients had docu-
mented lesions of the ventral portion of the capsule, but the 
lesion coverage of the dorsal parts of the capsule varied be-
tween groups. The observed response rates at last follow-up 
were 58% for group T, 67% for group D and 80% for group S. 
However, the observation in group S was based on only 
1  study with 5 patients.33 Based on the results we obtained 
from groups T and D, extending the lesion dorsally in the 
 internal capsule did not seem to significantly affect clinical 
 effectiveness. In a recent study, patients with OCD received 
bilateral single-shot radiosurgery targeting the midpoint of 
the ALIC, conceivably focusing on fibres connecting the 
 medial and orbitofrontal cortices, the head of the caudate and 
the midline thalamus.31 However, the observed response rate 
following this procedure was only 7% (1 responder of 
15 patients). In contrast, a repeat single-shot procedure or a 
double-shot procedure (D group), both targeting the capsule 
more ventrally (targeting the longitudinal fibre tracts that 
connect the anterior cingulate and orbitofrontal projections to 
the striatum, thalamus and brainstem), were associated with 
a significantly higher response rate (75%; 30 responders of 
40 patients).31 Although these results appear to indicate that 
the specific target in the ALIC could be a key to improving 
clinical outcomes, we could not rule out the possibility that 
the higher response rate in the single-shot repeat group was a 
delayed effect of radiosurgery, because the single-shot group 
was followed for only 9 months, not 12 months or longer.31
Our findings lent support to the view that the clinical effec-
tiveness of capsulotomy for OCD is closely linked to lesions 
of the ventral portion of the ALIC (in the coronal plane), ap-
proximately near the posterior putaminal border (in the axial 
plane).17 Anatomically, the ventral segment of the ALIC, em-
bedded within the ventral striatum and anterior commissure, 
is the region that carries fibres from the ventromedial pre-
frontal cortex and the orbital frontal cortex, whose dysfunc-
tion has long been implicated in the pathophysiology of 
OCD.28,36 In contrast, researchers have distinguished 4 dorsal 
components of the ALIC, which carry fibres of ventrolateral 
prefrontal cortex, dorsolateral prefrontal cortex, dorsal an-
terior cingulate cortex and medial prefrontal cortex.17 The ac-
tion of capsulotomy on OCD symptom severity could stem 
primarily from its effect on ventral capsule targets, thereby 
affecting brain functional networks involving the orbitofron-
tal cortex and ventromedial prefrontal cortex.28,36 In this con-
text, restricting lesion areas to the ventral capsule could be 
promising for reducing adverse effects without compromis-
ing therapeutic effects. It has also been hypothesized that the 
pathophysiological substrates of OCD, at least in some pa-
tients, are not symmetric, but instead are confined to 1 hemi-
sphere of the brain.6,32 If this hypothesis is valid, unilateral 
rather than bilateral capsulotomy can be used to alleviate 
OCD symptoms while reducing the risk of adverse effects. To 
date, however, only 1 study involving 4 patients has explored 
this therapeutic approach to OCD treatment.32
Treatment safety
Each ablative surgery was associated with risks of adverse 
effects. Overall, most of the documented adverse effects 
(about 90%) were transient and manageable. The most 
commonly reported mild and transient adverse event was 
headache, followed by cognitive deficits and behaviour 
problems. Of note, a relatively high incidence of headache 
was reported by Rasmussen and colleagues.31 These 
researchers observed that most patients who experienced 
headache had received gamma knife surgery. It seems 
plausible that the application of a relatively high peak dose of 
180 to 200 Gy could have contributed to patients’ post-
surgical headaches observed in this and other gamma knife 
studies.20,27,28,31 It may also help to explain patients’ vestibular 
adverse effects (nausea and vomiting).27,31 Indeed, studies 
using lower doses (e.g., 120, 140 or 150 Gy) have not reported 
such adverse effects.25,33,35
Capsulotomy was associated with higher incidence of mild 
and transient adverse effects than limbic system surgery. 
However, this finding could have been confounded by differ-
ences in the study methods used to assess adverse effects. 
Whereas limbic system lesion studies employed a more gen-
eral questioning method to elicit patient-reported effects, 
4 capsulotomy studies used active surveillance to ascertain 
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the occurrence of adverse effects.27,28,31,32 Active surveillance 
(e.g., Systematic Assessment for Treatment Emergent Effects) 
is more sensitive for detecting subtle discomfort such as head-
ache or paresthesia, and should be encouraged in studies to 
establish the full adverse effect profile associated with each 
ablative procedure. Accordingly, it remains to be determined 
whether the 2 ablative procedures genuinely differed from 
each other in incidence of mild and transient adverse effects.
The incidence of severe or permanent adverse effects was 
relatively low and did not differ greatly between capsulot-
omy and limbic system surgery. Notwithstanding their low 
incidence, more enduring adverse effects included personal-
ity changes (2.3%), as well as brain cysts or brain edema 
(1.5%), posing a health threat to patients. Although some of 
the enduring and serious adverse effects could be attributed 
to risks inherent in the medical procedure, others might be 
preventable by altering the size, exact location or nature of 
the therapeutic lesion. Indeed, the modification of currently 
used ablative interventions, as well as the development of 
novel, more sophisticated surgical techniques, would likely 
help prevent or reduce the incidence of both transient and 
enduring adverse effects. A possible barrier to reaching this 
goal remains a relative lack of knowledge about the precise 
causes and mechanisms of the adverse effects associated with 
ablative surgery.
We observed that the clinical effectiveness of capsulot-
omy for patient groups T and D was relatively similar. Fur-
thermore, the incidence rates of mild and transient adverse 
effects were comparable between the groups (median: 
T group 0.7%; D group 1.0%), but the nature of the adverse 
effect profiles differed between the groups. Group differ-
ences present in the incidence rates of severe or permanent 
adverse effects (median: T group 1.3%; D group 0.0%): pa-
tients in the T group showed personality changes and cog-
nitive deficits more often. Early capsulotomies for treating 
OCD used up to 3 isocentres (T group) to cover the majority 
of the ALIC. Subsequently, it was argued that reducing the 
extension of the lesions might help increase effectiveness 
and limit the risk of adverse effects.32 Unfortunately, no 
standard definition exists for the ventral portion of ALIC. 
As well, no consensus exists on whether ventral capsulot-
omy is superior to traditional capsulotomy. Although these 
results suggest that the MRI-based postsurgical lesion sub-
typing outlined by Miguel and colleagues17 has clinical util-
ity, it should be noted that the specific ablation technique 
used (e.g., radiofrequency ablation, radiosurgery, gamma 
knife, magnetic resonance–guided focused ultrasound) also 
differed between groups T and D. In any case, it would be 
worthwhile to determine whether restricting the lesion area 
to the ventral capsule is associated with fewer adverse 
 effects while maintaining or even improving the clinical 
effect iveness of the intervention.17,32
Challenges and future directions
This review indicated that ablative surgical procedures can 
offer a relatively safe and effective intervention for severe 
and treatment-resistant OCD, but the evidence also showed 
that a substantial portion of patients failed to respond clin-
ically to these interventions. Clinicians faced with this chal-
lenge have sometimes performed an additional or repeat 
 ablative surgical intervention in an effort to alleviate the pa-
tient’s OCD symptoms. In 1 study, for example, over half of 
the nonresponders after an initial cingulotomy showed a 
good clinical response to subsequent lesion interventions, in-
cluding a repeat cingulotomy and/or an additional subcau-
date tractotomy.34 However, the responder status (full, partial 
or nonresponse) was similar (p = 0.24) between patients who 
underwent a single cingulotomy (n = 30) and those who 
under went subsequent procedures (n = 27).34 Therefore, we 
cannot rule out the possibility that the earlier surgery exerted 
a latent effect in these patients, because they were followed 
for only 10.2 ± 1.7 months after the initial cingulotomy before 
the second procedure was conducted. As well, patients who 
receive multiple procedures have a higher risk of adverse 
 effects, including apathy and executive dysfunction, than 
 patients who receive a single surgery.32 Finally, it is import-
ant to ensure that patients receive adequate care and thera-
peutic interventions after ablative surgery. In particular, be-
havioural therapies (such as cognitive behavioural therapy 
with exposure and response prevention) can offer additional 
clinical benefits to patients after surgical treatment.31,53
Another approach to improving clinical effectiveness is to 
search for predictors of treatment response or prognostic bio-
markers. In the present review, we explored whether certain 
demographic and clinical characteristics of patients could 
serve as a predictor of clinical response. However, the results 
demonstrated that none of the variables examined had pre-
dictive validity. To reduce heterogeneity within patient 
groups and predict treatment response, a pathophysiology-
based approach to finding predictors could be more success-
ful, employing measures of altered brain function and struc-
ture implicated in OCD. For example, an MRI study found 
that the clinical response of patients who underwent cingu-
lotomy could be accurately predicted from measures of an-
terior cingulate cortex structure and connectivity.6 The identi-
fication of genetic or epigenetic markers is also a promising 
approach to clinical response prediction and personalized 
medicine, because OCD is likely an etiologically and genet-
ically heterogeneous disorder.4
Ablative surgery has been used for decades. So far, how-
ever, DBS (specifically, DBS of the ventral capsule or ventral 
striatum) is the only surgical intervention that has received 
approval from the United States Food and Drug Administra-
tion for OCD treatment.54 Indeed, reversibility and adjustabil-
ity represent major advantages of DBS. However, the rela-
tively high cost of DBS could be a problem for patients and 
health care providers. Other significant problems that may 
occur in DBS treatment involve battery failure, lead migra-
tion and device misplacement or malfunction.55,56 In contrast, 
neuroablation is relatively cost-effective and has a long-lasting 
clinical effect, rendering patients free of the inconvenience of 
battery changes and equipment maintenance. Emerging new 
techniques, including focused ultrasound and laser ablation, 
are pushing the field of ablative surgery forward in terms of both 
effectiveness and safety.55
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Limitations
This review had several limitations. First, the level of evi-
dence of most included studies was relatively low, limiting 
our ability to draw firm conclusions. Most studies were 
 observational in nature and did not adopt a comparative 
 research design. We identified only 1 randomized controlled 
trial,27 but its small sample size (n = 16) precluded extensive 
inferences. It should be noted that although randomized 
controlled trials are the standard of excellence for treatment 
studies, it is usually not ethical to assign a treatment (com-
pared to another treatment, no treatment or placebo) by ran-
domization rather than by patient and physician choice. The 
major concern is that the patient’s health could be compro-
mised by withholding appropriate treatment for the dura-
tion of the study.
Second, as we suggested earlier, the identification of 
 adverse effects in most studies was based on passive sur-
veillance. This method may have failed to detect subtle 
psychi atric symptoms and signs following ablative surgery, 
such as mood changes and suicidal ideation. This problem 
may have been particularly relevant when unstructured 
psychiatric interviews were conducted rather than formal 
systematic clinical assessments.24 Therefore, we could have 
underestimated the incidence of mild transient adverse 
 effects in this review. However, an important issue that re-
quires clarification is whether some of the reported adverse 
effects are linked to the neuroablative intervention itself 
and/or to the natural course of OCD or its comorbidity 
with other psychiatric disorders.20
Conclusion
Based on this review, we have tentatively drawn a number of 
conclusions about the effectiveness and safety of neuroabla-
tion for severe and treatment-resistant OCD. 
Each ablative surgical procedure can provide a relatively 
effective intervention for the primary symptoms of OCD. In 
most cases, ablative procedures can also alleviate symptoms 
of comorbid depression and anxiety disorders. Capsulotomy 
seems to be superior to limbic leucotomy and cingulotomy in 
terms of clinical effectiveness.
Each ablative surgery carries risks of adverse effects, which 
are mostly transient and manageable. In very rare cases, adverse 
effects are more enduring and pose a serious health concern. 
 Lesion subtyping in capsulotomy offers a promising ap-
proach to reducing adverse effects while seems not to affect 
effectiveness.
Finally, it should be emphasized that neuroablation is an 
appropriate treatment option for only rare cases of severe 
and treatment-resistant OCD. In addition, patient assessment 
and neurosurgical procedures should be carried out only at 
expert medical centres. The highest priorities for future re-
search are to improve the clinical effectiveness and to mini-
mize the risks of ablative surgical interventions.
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